GEDII

GEDiCube is an advanced artificial intelligence company specializing in the acceleration of drug discovery and the optimization of clinical trials within the oncology and precision medicine sectors. The company utilizes a proprietary AI platform that integrates multi-omic data to identify novel biomarkers and therapeutic targets, aiming to improve patient outcomes through earlier detection and more effective treatment strategies. GEDiCube's technology is designed to reduce the time and cost associated with drug development by predicting drug efficacy and safety profiles in silico. In 2023, the company entered into a definitive agreement to be acquired by Renovaro BioSciences, combining its AI capabilities with Renovaro's immunotherapy pipeline to create a vertically integrated health technology firm.